The four groups identified with such approach, i.e., POLE-mutant (POLEmut), MMR-deficient (dMMR), p53-abnormal (p53abn), and no specific molecular profile (NSMP), have been recently integrated in the European guidelines for endometrial cancer management (5, 6) with important clinical implications as the following:. This evidence concerns the gene TP53 and endometrial cancer.